|
2024
|
Invention
|
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment... |
|
|
Invention
|
Modular chimeric antigen receptor. The invention relates to chimeric activating receptor (CAR) si... |
|
|
Invention
|
Methods for purifying heteromultimeric antibodies. The invention relates to a method of purifying... |
|
2023
|
Invention
|
Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies. The... |
|
|
Invention
|
Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering. The pre... |
|
|
Invention
|
Nectin-4 binding agents. The invention relates to antibodies and antibody fragment that bind to N... |
|
|
P/S
|
Préparations pharmaceutiques pour la prévention et le traitement du cancer. |
|
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, immunoproliferative disorders, inflammat... |
|
2022
|
Invention
|
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a. Multisp... |
|
|
Invention
|
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2. The present inventi... |
|
|
Invention
|
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a. The inv... |
|
|
Invention
|
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a. Multisp... |
|
|
Invention
|
Immunohistochemistry methods and kir3dl2-specific reagents. The present invention relates to anti... |
|
|
Invention
|
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to... |
|
2021
|
Invention
|
Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123. The present disclos... |
|
|
Invention
|
Treatment of cancer. The invention relates to antigen-binding proteins capable of binding to Nect... |
|
|
P/S
|
Chemical or biotechnological products for industry and science, namely, polypeptides and proteins... |
|
|
Invention
|
Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab. The present invention conce... |
|
|
Invention
|
Cell surface mica and micb detection using antibodies. The present disclosure relates to research... |
|
|
Invention
|
Cancer treatment methods using anti-cd73 antibodies. The disclosure relates to methods and compos... |
|
|
Invention
|
Use of cd160 as a biomarker in acute myeloid leukemia. Natural killer (NK) cells are innate cytot... |
|
|
P/S
|
Chemical or biotechnological products for industry and science, biological preparations, in parti... |
|
|
Invention
|
Treatment of cancer. The present invention provides antigen-binding proteins capable of binding t... |
|
2020
|
Invention
|
Treatment of cancer with ilt-2 inhibitors. This invention relates to the use of a NKG2A-neutraliz... |
|
|
Invention
|
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatme... |
|
|
Invention
|
Cd73 blocking antibodies. The present invention relates to antibodies, and fragments thereof, tha... |
|
|
Invention
|
Treatment of t cell lymphoma. The present invention relates to methods for the treatment of T cel... |
|
2019
|
Invention
|
Compounds and methods for treatment of head and neck cancer. This invention relates to the use of... |
|
|
Invention
|
Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies. This invention relates to agent... |
|
|
Invention
|
Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibo... |
|
|
Invention
|
Compositions and methods for treating cancer. The present invention relates to antigen-binding co... |
|
|
Invention
|
Treatment of cancer. The present invention relates to the use of NKG2A-neutralizing agents and PD... |
|
|
Invention
|
Methods for treating cancer by targeting nidogen-1. This invention relates to methods of treating... |
|
|
Invention
|
Treatment of head and neck cancer. This invention relates to the use of NKG2A-targeting agents fo... |
|
2018
|
Invention
|
Multispecific antigen binding proteins. Multimeric multispecific proteins that bind multiple targ... |
|
|
Invention
|
Potentiating the effect of atp release. The present invention relates to methods of using compoun... |
|
|
Invention
|
Antibodies with functionalized glutamine residues. The present application relates to methods for... |
|
|
Invention
|
Restoration of t cell activity via the cd39/cd73 axis. The present invention relates to methods o... |
|
|
Invention
|
Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating can... |
|
|
Invention
|
Siglec-9-neutralizing antibodies. Siglec-9 has inhibitory activity in immune cells. This inventio... |
|
|
Invention
|
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide. The present invent... |
|
|
Invention
|
Nkp46 binding agents. The present invention provides antigen-binding proteins capable of binding ... |
|
2017
|
Invention
|
Heterodimeric antigen binding proteins. Provided are heterodimeric proteins formed from dimerizat... |
|
|
Invention
|
Nkp46 ligand. This invention relates to natural ligands of NKp46 and compositions and methods for... |
|
|
Invention
|
Treatment with anti-kir3dl2 agents. This disclosure relates to the use of KIR3DL2-targeting agent... |
|
|
P/S
|
Pharmaceutical preparations and substances. |
|
|
Invention
|
Anti-cd39 antibodies. The present invention relates to antibodies that inhibit CD39. The inventio... |
|
|
Invention
|
Anti-cd39 antibodies. The present invention relates to antigen-binding compounds that inhibit CD3... |
|
|
Invention
|
Anti-mica antibodies. The present invention provides antigen-binding proteins capable of binding ... |
|
|
Invention
|
Siglec neutralizing antibodies. This invention relates to agents that bind human Siglecs having i... |
|
|
Invention
|
Neutralization of inhibitory pathways in lymphocytes. This invention relates to the use of NKG2A-... |
|
2016
|
Invention
|
Variable regions for nkp46 binding proteins. NKp46-binding immunoglobulin variable regions, and p... |
|
|
Invention
|
Cd39 vascular isoform targeting agents. The present disclosure relates to antigen-binding compoun... |
|
|
Invention
|
Siglec-10 antibodies. This disclosure relates to agents that bind and neutralize the inhibitory a... |
